Details of Disease

General Information of Disease (ID: DISV1LU6)

• Disease Name: Classic Hodgkin lymphoma
• Synonyms: lymphoma, Hodgkin, classic; Hodgkin lymphoma, susceptibility to; Hodgkin disease; Chl; classical Hodgkin lymphoma; classic Hodgkin disease; classical Hodgkin's lymphoma
• Definition: Classical Hodgkin lymphoma (CHL) is a B-cell lymphoma characterized histologically by the presence of large mononuclear Hodgkin cells and multinucleated Reed-Sternberg (HRS) cells.
• Disease Hierarchy:
  DISX2OUL: Hodgkin lymphoma
  DISV1LU6: Classic Hodgkin lymphoma
• Disease Identifiers:
  MONDO ID: MONDO_0009348
  MESH ID: D006689
  UMLS CUI: C0019829
  OMIM ID: 236000
  MedGen ID: 9283
  HPO ID: HP:0012189
  Orphanet ID: 391
  SNOMED CT ID: 1163005009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 26 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Betamethasone	DMAHJEF	Approved	Small molecular drug	[1]
Bleomycin	DMNER5S	Approved	Small molecular drug	[2]
Brentuximab vedotin	DMWLC57	Approved	Monoclonal antibody	[3]
Chlorambucil	DMRKE63	Approved	Small molecular drug	[4]
Clofarabine	DMCVJ86	Approved	Small molecular drug	[5]
Cortisone Acetate	DMG8K57	Approved	Small molecular drug	[6]
Cyclophosphamide	DM4O2Z7	Approved	Small molecular drug	[7]
Dacarbazine	DMNPZL4	Approved	Small molecular drug	[8]
Dexamethasone	DMMWZET	Approved	Small molecular drug	[9]
Doxorubicin	DMVP5YE	Approved	Small molecular drug	[10]
DTI-015	DMXZRW0	Approved	Small molecular drug	[11]
Fludarabine	DMVRLT7	Approved	Small molecular drug	[12]
Hydrocortisone	DMGEMB7	Approved	Small molecular drug	[13]
Lomustine	DMMWSUL	Approved	Small molecular drug	[14]
Mechlorethamine	DM0CVXA	Approved	Small molecular drug	[15]
Melphalan	DMOLNHF	Approved	Small molecular drug	[16]
Methylprednisolone	DM4BDON	Approved	Small molecular drug	[17]
Mycophenolate mofetil	DMPQAGE	Approved	Small molecular drug	[18]
Mycophenolic acid	DMRBMAU	Approved	NA	[19]
Prednisolone	DMQ8FR2	Approved	Small molecular drug	[20]
Prednisone	DM2HG4X	Approved	Small molecular drug	[21]
Tacrolimus	DMZ7XNQ	Approved	Small molecular drug	[22]
Thiotepa	DMIZKOP	Approved	Small molecular drug	[23]
Triamcinolone	DM98IXF	Approved	Small molecular drug	[24]
Vinblastine	DM5TVS3	Approved	Small molecular drug	[25]
Vincristine	DMINOX3	Approved	Small molecular drug	[26]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 151 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ACE2	TTUI5H7	Limited	Genetic Variation	[27]
CASP10	TTX5HEK	Limited	Genetic Variation	[28]
CD19	TTW640A	Limited	Biomarker	[29]
CD27	TTDO1MV	Limited	Altered Expression	[30]
CD70	TTNCIE0	Limited	Genetic Variation	[31]
CDC25A	TTLZS4Q	Limited	Altered Expression	[32]
DPP4	TTDIGC1	Limited	Biomarker	[33]
GAL	TTXZAJ5	Limited	Biomarker	[34]
GAP43	TTSGLN5	Limited	Biomarker	[34]
GATA3	TT45KOB	Limited	Biomarker	[35]
HEXA	TTJI5JW	Limited	Genetic Variation	[36]
KDM4C	TTV8CRH	Limited	Biomarker	[37]
TCF3	TTULOD8	Limited	Genetic Variation	[38]
TNNI3	TTNLDK6	Limited	Biomarker	[39]
GSTP1	TT40K12	Disputed	Genetic Variation	[40]
CCR5	TTJIH8Q	moderate	Biomarker	[41]
FASLG	TTO7014	moderate	Altered Expression	[42]
SOCS1	TT8COJM	moderate	Genetic Variation	[43]
SOST	TTYRO4F	moderate	Altered Expression	[44]
ADAM10	TTVXEGU	Strong	Biomarker	[45]
AGRP	TT4DE1O	Strong	Biomarker	[46]
AHSG	TTKF4WV	Strong	Altered Expression	[47]
AICDA	TTKRTP6	Strong	Biomarker	[48]
AOC3	TT7HC21	Strong	Biomarker	[49]
APOC3	TTXOZQ1	Strong	Biomarker	[50]
BAK1	TTFM7V0	Strong	Genetic Variation	[51]
BCL11A	TTR61MW	Strong	Genetic Variation	[52]
BTK	TTGM6VW	Strong	Biomarker	[53]
CALCR	TTLWS2O	Strong	Biomarker	[54]
CCR3	TTD3XFU	Strong	Altered Expression	[55]
CCR4	TT7HQD0	Strong	Genetic Variation	[56]
CD274	TT8ZLTI	Strong	Altered Expression	[57]
CD37	TTFCW29	Strong	Altered Expression	[58]
CD40LG	TTIJP3Q	Strong	Biomarker	[59]
CD5	TTEGYK1	Strong	Biomarker	[60]
CD58	TT5KSBY	Strong	Altered Expression	[61]
CD83	TTT9MRQ	Strong	Biomarker	[62]
CDC25C	TTESBNC	Strong	Altered Expression	[63]
CDK2	TT7HF4W	Strong	Biomarker	[64]
CDKN2C	TTBRUGA	Strong	Altered Expression	[65]
CETP	TTFQAYR	Strong	Genetic Variation	[66]
CFLAR	TTJZQYH	Strong	Altered Expression	[67]
CSF1	TT0IQER	Strong	Biomarker	[68]
CXCR5	TTIW59R	Strong	Altered Expression	[69]
DDR1	TTI1FPZ	Strong	Biomarker	[70]
DRD3	TT4C8EA	Strong	Biomarker	[71]
EML4	TT92GY4	Strong	Genetic Variation	[72]
ENPP2	TTSCIM2	Strong	Biomarker	[73]
EPHA7	TTAHTVG	Strong	Biomarker	[74]
FCGR3A	TTIFOC0	Strong	Biomarker	[75]
FCGRT	TTKLPHO	Strong	Genetic Variation	[76]
FGF23	TT2IZ4K	Strong	Altered Expression	[77]
FMNL1	TTW20PQ	Strong	Altered Expression	[78]
FOXC1	TTNT3YA	Strong	Altered Expression	[79]
GLO1	TTV9A7R	Strong	Genetic Variation	[80]
GSTA1	TT4P8DE	Strong	Biomarker	[40]
GUCY2D	TTWNFC2	Strong	Biomarker	[81]
GZMB	TTKEPHX	Strong	Altered Expression	[82]
HAMP	TTRV5YJ	Strong	Altered Expression	[83]
HBB	TTM6HK1	Strong	Genetic Variation	[84]
HDAC10	TTYHPU6	Strong	Biomarker	[85]
HDAC11	TT8K17W	Strong	Biomarker	[85]
HLA-DRB1	TTUXSTW	Strong	Genetic Variation	[86]
HLA-G	TTLKFB3	Strong	Altered Expression	[87]
HTR5A	TTRUFDT	Strong	Genetic Variation	[88]
HTT	TTIWZ0O	Strong	Biomarker	[89]
ID2	TTW8A5N	Strong	Altered Expression	[90]
IFNA2	TTSIUJ9	Strong	Biomarker	[91]
IFNL3	TTRF4Q2	Strong	Biomarker	[92]
IL11RA	TTZPLJS	Strong	Altered Expression	[93]
IL12A	TTRTK6Y	Strong	Genetic Variation	[94]
IL12B	TTGW72V	Strong	Genetic Variation	[95]
IL13	TT0GVCH	Strong	Altered Expression	[96]
IL13RA2	TTMPZ7V	Strong	Altered Expression	[97]
IL31	TT1RJXK	Strong	Altered Expression	[98]
IL4R	TTDWHC3	Strong	Genetic Variation	[99]
IL5	TTPREZD	Strong	Altered Expression	[100]
JAK2	TTRMX3V	Strong	Genetic Variation	[101]
KIR2DS1	TTVWAGF	Strong	Biomarker	[102]
KIR3DL2	TTQH3N0	Strong	Genetic Variation	[102]
LAIR1	TTSI7A8	Strong	Biomarker	[103]
LGALS1	TTO3NYT	Strong	Altered Expression	[104]
LMO2	TTFX379	Strong	Altered Expression	[105]
LTB	TTHQ6US	Strong	Biomarker	[106]
LY75	TTG180Q	Strong	Altered Expression	[107]
MAPKAP1	TTWDKCL	Strong	Biomarker	[108]
MAZ	TT059DA	Strong	Biomarker	[109]
MC1R	TT0MV2T	Strong	Genetic Variation	[110]
MSTN	TTM8I2X	Strong	Biomarker	[111]
MTNR1A	TT0WAIE	Strong	Genetic Variation	[112]
MTNR1B	TT32JK8	Strong	Biomarker	[112]
NAAA	TTMN4HY	Strong	Biomarker	[113]
NAPRT	TTVR1FW	Strong	Altered Expression	[114]
NCK1	TTMA3VF	Strong	Genetic Variation	[51]
NFKB2	TTKLNRV	Strong	Biomarker	[115]
NFKBIA	TTSHAEB	Strong	Altered Expression	[116]
NME1	TTDY8JH	Strong	Altered Expression	[117]
NPM1	TTHBS98	Strong	Altered Expression	[118]
NR1H3	TTECBXN	Strong	Genetic Variation	[119]
PDCD1LG2	TTW14O3	Strong	Altered Expression	[120]
PIM2	TT69J2Z	Strong	Biomarker	[121]
PMS1	TTX1ISF	Strong	Genetic Variation	[122]
PRAME	TTPH7T0	Strong	Biomarker	[123]
PSIP1	TTH9LDP	Strong	Altered Expression	[124]
PSMB9	TTOUSTQ	Strong	Biomarker	[125]
PTH	TT6F7GZ	Strong	Biomarker	[126]
PTPN1	TTELIN2	Strong	Biomarker	[127]
REG3A	TTL4H8N	Strong	Biomarker	[128]
REL	TT1ZCTH	Strong	Biomarker	[129]
RGS6	TTJ96M8	Strong	Altered Expression	[130]
RXRA	TT6PEUO	Strong	Genetic Variation	[119]
S100A12	TTQ4ESF	Strong	Biomarker	[131]
SLC26A4	TT7X02I	Strong	Genetic Variation	[132]
SLC27A4	TT20AYF	Strong	Genetic Variation	[133]
SLC29A1	TTLXAKE	Strong	Altered Expression	[134]
SLC40A1	TT6Y1PG	Strong	Altered Expression	[135]
SLC6A8	TTYUHB5	Strong	Biomarker	[54]
SLCO1B3	TTU86P0	Strong	Genetic Variation	[136]
SNAP25	TTYQWA0	Strong	Biomarker	[137]
STAT6	TTWOE1T	Strong	Biomarker	[138]
TBX21	TTNF9PH	Strong	Biomarker	[139]
TIGIT	TTWNL74	Strong	Altered Expression	[140]
TMPRSS6	TTL9KE7	Strong	Biomarker	[112]
TNFAIP3	TT5W0IO	Strong	Genetic Variation	[141]
TNFRSF17	TTZ3P4W	Strong	Biomarker	[142]
TNFRSF25	TTDV6BQ	Strong	Altered Expression	[143]
TNFSF13B	TTWMIDN	Strong	Altered Expression	[144]
TRPC4	TTX0H5W	Strong	Biomarker	[145]
TUSC2	TTJ8O14	Strong	Biomarker	[128]
UCHL1	TTX9IFP	Strong	Biomarker	[146]
UCP1	TTI12YJ	Strong	Genetic Variation	[147]
UGT1A1	TT34ZAF	Strong	Genetic Variation	[148]
BCL2L2	TTQ79W8	Definitive	Altered Expression	[149]
CCL11	TTCF05Y	Definitive	Altered Expression	[55]
CCL22	TTBTWI1	Definitive	Biomarker	[150]
CD79B	TTBN5I7	Definitive	Genetic Variation	[151]
COPS5	TTSTNJR	Definitive	Altered Expression	[152]
CR2	TT0HUN7	Definitive	Biomarker	[153]
CSF3	TT5TQ2W	Definitive	Genetic Variation	[154]
FCER2	TTCH6MU	Definitive	Altered Expression	[155]
GRM5	TTHS256	Definitive	Biomarker	[156]
IL3RA	TTENHJ0	Definitive	Biomarker	[157]
LPL	TTOF3WZ	Definitive	Biomarker	[158]
NPSR1	TTV1C0Z	Definitive	Genetic Variation	[159]
PDCD1	TTNBFWK	Definitive	Biomarker	[160]
PIM1	TTTN5QW	Definitive	Altered Expression	[161]
SCT	TTOBVIN	Definitive	Biomarker	[162]
SDC1	TTYDSVG	Definitive	Altered Expression	[163]
SLC22A2	TT0XOJN	Definitive	Biomarker	[164]
TNFRSF9	TTPW9LJ	Definitive	Altered Expression	[165]
ZAP70	TTUMHT8	Definitive	Genetic Variation	[166]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCC6	DT582KR	Strong	Biomarker	[167]

This Disease Is Related to 4 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ACP3	DEDW5H6	Strong	Biomarker	[128]
BLMH	DECH1VP	Strong	Genetic Variation	[168]
GSTT1	DE3PKUG	Strong	Genetic Variation	[169]
UBASH3B	DE10BJ5	Strong	Biomarker	[170]

This Disease Is Related to 231 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACSBG1	OTM040MW	Limited	Biomarker	[171]
ALLC	OTZE4XV7	Limited	Genetic Variation	[172]
BATF3	OTI61WXQ	Limited	Biomarker	[173]
CCHCR1	OT22C116	Limited	Biomarker	[174]
CCL4L2	OTDBSXOU	Limited	Altered Expression	[96]
CYP4V2	OTQKNK0D	Limited	Biomarker	[175]
ERFE	OTSES1HA	Limited	Biomarker	[176]
GLIS2	OTOUUV1X	Limited	Altered Expression	[177]
IBTK	OTB2GM4G	Limited	Altered Expression	[178]
KLHDC8B	OTKP6LCR	Limited	Unknown	[179]
MCM3AP	OT895FEC	Limited	Biomarker	[180]
NINL	OTWIK6HT	Limited	Genetic Variation	[181]
NRSN1	OT1KKXC8	Limited	Biomarker	[34]
RAPH1	OTMQXW7S	Limited	Biomarker	[171]
RASGRP1	OTX9WN2E	Limited	Altered Expression	[182]
RELN	OTLKMW1O	Limited	Biomarker	[183]
SELENBP1	OT3NZNTR	Limited	Biomarker	[174]
SKI	OT4KJ8F6	Limited	Biomarker	[184]
TBP	OT6C0S52	Limited	Biomarker	[185]
AHI1	OT8K2YWY	moderate	Genetic Variation	[186]
EBAG9	OTTQLQCP	moderate	Biomarker	[187]
IL10RA	OTOX3D1D	moderate	Genetic Variation	[188]
MGP	OTZWU3FU	moderate	Biomarker	[189]
NIPBL	OTF6OOLU	moderate	Genetic Variation	[190]
OPCML	OT93PQ6Y	moderate	Posttranslational Modification	[191]
ACOXL	OTW680HT	Strong	Genetic Variation	[51]
ADAM11	OTPTVW5W	Strong	Altered Expression	[192]
ADARB1	OTGKSZEV	Strong	Altered Expression	[193]
ADD1	OTTF68DC	Strong	Biomarker	[194]
AGO2	OT4JY32Q	Strong	Genetic Variation	[195]
ALG1	OTVXPA9E	Strong	Genetic Variation	[112]
ALMS1	OTW66JKS	Strong	Genetic Variation	[196]
AMPD1	OTU17BCI	Strong	Genetic Variation	[197]
ANP32B	OT3SQMLU	Strong	Altered Expression	[144]
APH1A	OT97F1TU	Strong	Biomarker	[198]
ARHGAP24	OTCQCEZS	Strong	Genetic Variation	[199]
ARHGDIB	OT9PD6CS	Strong	Altered Expression	[200]
ARHGEF7	OT9BPJCL	Strong	Altered Expression	[124]
ASAP1	OT4DLRYY	Strong	Biomarker	[128]
ASAP2	OTGEXULW	Strong	Biomarker	[128]
ATF1	OT251CI0	Strong	Genetic Variation	[201]
ATF7IP	OTU6ZA7F	Strong	Biomarker	[202]
BCL10	OT47MCLI	Strong	Genetic Variation	[203]
BCL3	OT1M5B95	Strong	Genetic Variation	[204]
BCR	OTCN76C1	Strong	Genetic Variation	[205]
BMF	OT90NSLI	Strong	Genetic Variation	[51]
CBFA2T2	OTNOIB23	Strong	Altered Expression	[206]
CBFA2T3	OTOJ10S1	Strong	Posttranslational Modification	[207]
CCL8	OTCTWYN8	Strong	Biomarker	[208]
CD247	OT45FGUX	Strong	Altered Expression	[209]
CD302	OTX580VU	Strong	Altered Expression	[107]
CD79A	OTOJC8DV	Strong	Biomarker	[146]
CD99	OTPUZ5DE	Strong	Biomarker	[210]
CDKN3	OTBE3H07	Strong	Altered Expression	[211]
CHRDL1	OTGMWVVA	Strong	Biomarker	[212]
CIB3	OT97EYB9	Strong	Genetic Variation	[51]
CLTA	OTLHOXMQ	Strong	Biomarker	[81]
CMTR2	OT82FBWS	Strong	Biomarker	[213]
COL4A2	OTJK1LKN	Strong	Biomarker	[214]
CUX1	OTU1LCNJ	Strong	Biomarker	[215]
CXCL3	OTSL94KH	Strong	Altered Expression	[216]
CYB5B	OTONNAV1	Strong	Genetic Variation	[217]
CYP4Z1	OTKRGJBG	Strong	Genetic Variation	[218]
DCT	OTYVNTBG	Strong	Biomarker	[145]
DCTN6	OTI8PIN9	Strong	Altered Expression	[219]
DEDD	OTIL349E	Strong	Altered Expression	[220]
DIXDC1	OT87DXEG	Strong	Biomarker	[221]
DLEC1	OTMKKBUW	Strong	Biomarker	[222]
DRAM2	OTBOCZH8	Strong	Biomarker	[223]
DROSHA	OTCE68KZ	Strong	Genetic Variation	[224]
DTNB	OTX1HKM7	Strong	Genetic Variation	[51]
E2F6	OT2PN28R	Strong	Altered Expression	[225]
EBF1	OTZ61YYH	Strong	Biomarker	[226]
EIF2S1	OTM0GDTP	Strong	Altered Expression	[227]
ELL2	OTZJRTFM	Strong	Genetic Variation	[51]
EMP1	OTSZHUHQ	Strong	Biomarker	[228]
ENHO	OT91QASK	Strong	Genetic Variation	[119]
FCGR3B	OTSLSPZG	Strong	Biomarker	[75]
FNDC3A	OTUX3S2I	Strong	Genetic Variation	[116]
FOXD1	OT80PRHS	Strong	Altered Expression	[79]
FOXN3	OTOJYJZP	Strong	Altered Expression	[79]
GCSAM	OTZNOPYK	Strong	Altered Expression	[229]
GFER	OTVK43OK	Strong	Biomarker	[230]
GLRX3	OTUPAU1N	Strong	Biomarker	[231]
GRAMD1B	OTCG1GX2	Strong	Genetic Variation	[51]
GRHL3	OT1V4ZEH	Strong	Biomarker	[232]
GTF2H4	OTPD1DIU	Strong	Altered Expression	[124]
HABP4	OTU223PA	Strong	Biomarker	[233]
HARS1	OTHOEOTS	Strong	Biomarker	[234]
HCLS1	OTX7WGYN	Strong	Biomarker	[235]
HERPUD1	OT9EROL6	Strong	Biomarker	[137]
HGS	OTCYYCAC	Strong	Biomarker	[234]
HIP1	OT7AKCFQ	Strong	Biomarker	[236]
HJV	OT4235J2	Strong	Altered Expression	[237]
HLA-DPB1	OTW8JHU2	Strong	Biomarker	[238]
HLX	OT7DTH46	Strong	Altered Expression	[177]
HOXB9	OTMVHQOU	Strong	Altered Expression	[239]
HRNR	OT560QR5	Strong	Altered Expression	[240]
IFI27	OTI2XGIT	Strong	Altered Expression	[219]
IKBKE	OT5VYOSM	Strong	Biomarker	[241]
IL17RA	OTVVI8ER	Strong	Altered Expression	[242]
IL3	OT0CQ35N	Strong	Altered Expression	[243]
IMMT	OTBDSLE7	Strong	Altered Expression	[244]
ISL1	OTVNVKAX	Strong	Altered Expression	[245]
KDSR	OTCIES3H	Strong	Biomarker	[246]
KHSRP	OTDHZARB	Strong	Biomarker	[235]
KIR3DS1	OTJWIO4T	Strong	Genetic Variation	[102]
LIPC	OTZY5SC9	Strong	Genetic Variation	[247]
LPP	OT6TU8SE	Strong	Genetic Variation	[51]
MAL	OTBM30SW	Strong	Altered Expression	[248]
MAP1S	OT5WUD4C	Strong	Biomarker	[249]
MARCHF10	OTAYGHDM	Strong	Genetic Variation	[250]
MBTPS2	OT67CC7W	Strong	Genetic Variation	[251]
MCC	OTQVI1EM	Strong	Biomarker	[252]
MEF2A	OTV2SF6E	Strong	Genetic Variation	[253]
MEF2B	OT880SE6	Strong	Biomarker	[254]
MIB1	OT5C404P	Strong	Biomarker	[255]
MNX1	OTXP9FH1	Strong	Altered Expression	[256]
MORC4	OTJBEHNE	Strong	Altered Expression	[257]
MPP1	OTA2ENZQ	Strong	Biomarker	[235]
MRPS30	OTDXIAGG	Strong	Biomarker	[128]
MRTFA	OTCVXASM	Strong	Altered Expression	[258]
MT1B	OTUA4FFH	Strong	Genetic Variation	[112]
MT1E	OTXJKU4Y	Strong	Genetic Variation	[112]
MT1F	OTZVUYG1	Strong	Genetic Variation	[112]
MT1G	OTAV1OCR	Strong	Genetic Variation	[112]
MT1H	OT0MVBM6	Strong	Genetic Variation	[112]
MT1M	OTVT8PLU	Strong	Genetic Variation	[112]
MT1X	OT9AKFVS	Strong	Genetic Variation	[112]
MTHFD2	OT1LQSGX	Strong	Biomarker	[259]
MTPAP	OT6HQ02S	Strong	Biomarker	[128]
MXD1	OTS5CTHX	Strong	Genetic Variation	[197]
NAPSA	OT6F8IAL	Strong	Altered Expression	[260]
NCAPH2	OTSASNX6	Strong	Genetic Variation	[51]
NCKIPSD	OT24UORN	Strong	Genetic Variation	[261]
NCOR2	OTY917X0	Strong	Genetic Variation	[262]
NKX2-2	OTDCOYNG	Strong	Altered Expression	[263]
NOL3	OT1K0L0D	Strong	Biomarker	[147]
NPAT	OT1ZU6JB	Strong	Genetic Variation	[264]
OR10A4	OTYYB8SY	Strong	Altered Expression	[265]
OTX2	OTTV05B1	Strong	Altered Expression	[266]
P4HB	OTTYNYPF	Strong	Biomarker	[267]
PAK3	OT80M3BV	Strong	Biomarker	[167]
PAPOLA	OTPHD65D	Strong	Biomarker	[128]
PAPPA2	OTXYGTUZ	Strong	Biomarker	[268]
PDAP1	OTJSWMOD	Strong	Biomarker	[128]
PDIA6	OT8YBR17	Strong	Altered Expression	[269]
PIK3R2	OTZSUQK5	Strong	Altered Expression	[206]
PIK3R3	OTXGJ8N1	Strong	Biomarker	[235]
PITX3	OTE2KT8P	Strong	Biomarker	[270]
POLG2	OTDBMZJB	Strong	Biomarker	[235]
POLM	OT0SRIP4	Strong	Altered Expression	[271]
POT1	OTNBXJCQ	Strong	Genetic Variation	[272]
POU2AF1	OTOO6WHL	Strong	Genetic Variation	[273]
POU4F3	OTILD0XS	Strong	Biomarker	[274]
PPP1R12C	OT9Q86JO	Strong	Altered Expression	[206]
PPP1R13B	OTC88VQO	Strong	Altered Expression	[206]
PPP1R1A	OTGTAGCV	Strong	Genetic Variation	[275]
PRSS3	OTN3S5YB	Strong	Biomarker	[276]
PSMD12	OTWICA51	Strong	Biomarker	[235]
PTX3	OTPXHRKU	Strong	Biomarker	[270]
PVALB	OTZW1WVQ	Strong	Biomarker	[232]
RAG1	OTV131E4	Strong	Biomarker	[277]
RAG2	OTG9UYTW	Strong	Biomarker	[277]
RANBP2	OTFG5CVF	Strong	Biomarker	[145]
RANGAP1	OTZGD3LJ	Strong	Altered Expression	[278]
RELB	OTU3QYEF	Strong	Biomarker	[279]
RHOH	OT1J9SEB	Strong	Genetic Variation	[280]
RING1	OTCWTAX0	Strong	Biomarker	[225]
RLN2	OTY3OG71	Strong	Biomarker	[281]
RPS2	OTSMTZVB	Strong	Altered Expression	[282]
RPTN	OTOAA25U	Strong	Altered Expression	[240]
RPTOR	OT4TQZ9F	Strong	Biomarker	[108]
RTEL1	OTI3PJCT	Strong	Genetic Variation	[283]
RYBP	OTZZ4P2Z	Strong	Altered Expression	[284]
SCYL1	OTQ0IN7P	Strong	Biomarker	[285]
SEPTIN2	OT3G33TM	Strong	Biomarker	[210]
SERPINA5	OTTZXPGD	Strong	Biomarker	[286]
SFPQ	OTLCIAPJ	Strong	Biomarker	[198]
SH2D1A	OTLU49I5	Strong	Biomarker	[287]
SIGLEC7	OTNDLURR	Strong	Biomarker	[235]
SLN	OTERIU75	Strong	Biomarker	[288]
SMPX	OTLSHGBF	Strong	Biomarker	[289]
SOAT1	OTB4Y5RJ	Strong	Altered Expression	[290]
SOX1	OTVI1RAR	Strong	Biomarker	[291]
SP140	OTQZHFMT	Strong	Genetic Variation	[51]
SPIB	OTO4YKYI	Strong	Biomarker	[292]
SPON2	OTE7JLNM	Strong	Altered Expression	[293]
SRSF5	OTC5WP98	Strong	Biomarker	[234]
SSX1	OTZ7NRCY	Strong	Altered Expression	[294]
SSX2	OT2Z6RLL	Strong	Altered Expression	[294]
STAT5A	OTBSJGN3	Strong	Altered Expression	[281]
TBC1D9	OTSSCTB5	Strong	Biomarker	[295]
TCHHL1	OTAMOJGN	Strong	Altered Expression	[240]
TCOF1	OT4BOYTM	Strong	Genetic Variation	[296]
TICAM2	OTK7GIJ5	Strong	Altered Expression	[219]
TM7SF2	OTILU5S7	Strong	Biomarker	[27]
TMED7	OTONO8E6	Strong	Altered Expression	[219]
TNFSF8	OTDYGDJ3	Strong	Biomarker	[297]
TNPO1	OT7W2CM8	Strong	Biomarker	[108]
TRIM33	OT0KS4J7	Strong	Biomarker	[298]
TSPYL2	OTGGW2EF	Strong	Biomarker	[299]
BAG6	OT4Z0S2U	Definitive	Genetic Variation	[300]
CIITA	OTRJNZFO	Definitive	Altered Expression	[301]
CLEC16A	OTLGV5SV	Definitive	Genetic Variation	[186]
CLIP1	OTTGAEJE	Definitive	Biomarker	[302]
CLSTN2	OT2PJYHX	Definitive	Genetic Variation	[38]
COL11A2	OT3BQUBH	Definitive	Genetic Variation	[300]
COL15A1	OTTFKK18	Definitive	Biomarker	[302]
DEXI	OT60W9CN	Definitive	Biomarker	[301]
HBS1L	OTA3U1N6	Definitive	Genetic Variation	[300]
HLA-DRA	OT7KZMP2	Definitive	Genetic Variation	[300]
IRF4	OT1DHQ1P	Definitive	Altered Expression	[303]
LY6G6C	OTV7F59X	Definitive	Genetic Variation	[300]
LY6G6D	OTG75QOC	Definitive	Genetic Variation	[300]
MAGEH1	OTVE05K7	Definitive	Biomarker	[302]
MICB	OTS2DVDW	Definitive	Genetic Variation	[300]
MIXL1	OT584VOQ	Definitive	Altered Expression	[304]
MPIG6B	OTVNKQWA	Definitive	Genetic Variation	[300]
MSX1	OT5U41ZP	Definitive	Genetic Variation	[266]
NCOA5	OTOGWTWB	Definitive	Genetic Variation	[273]
NFKBIE	OTLAYEL9	Definitive	Genetic Variation	[305]
PBX2	OTEBYCAW	Definitive	Genetic Variation	[300]
POU2F2	OTPV0J0C	Definitive	Altered Expression	[164]
PRDM1	OTQLSVBS	Definitive	Altered Expression	[306]
PRRC2A	OTBX6FM5	Definitive	Genetic Variation	[300]
PTPN22	OTDCNTC3	Definitive	Genetic Variation	[273]
SLC12A9	OTR7VRAK	Definitive	Altered Expression	[307]
SPI1	OTVCA1D0	Definitive	Altered Expression	[164]
TRAF1	OTTLM5RU	Definitive	Altered Expression	[308]
TRAF3	OT5TQBGV	Definitive	Altered Expression	[309]

References

• [1] Betamethasone FDA Label
• [2] Bleomycin FDA Label
• [3] Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults. Blood. 2023 Apr 27;141(17):2075-2084.
• [4] Chlorambucil FDA Label
• [5] Clofarabine FDA Label
• [6] Cortisone acetate FDA Label
• [7] Cyclophosphamide FDA Label
• [8] Dacarbazine FDA Label
• [9] Dexamethasone FDA Label
• [10] Doxorubicin FDA Label
• [11] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [12] Fludarabine FDA Label
• [13] Hydrocortisone FDA Label
• [14] Lomustine FDA Label
• [15] Mechlorethamine FDA Label
• [16] Melphalan FDA Label
• [17] Methylprednisolone FDA Label
• [18] Mycophenolate mofetil FDA Label
• [19] Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database. Pathol Res Pract. 2018 Nov;214(11):1854-1867.
• [20] Prednisolone FDA Label
• [21] Prednisone FDA Label
• [22] Tacrolimus FDA Label
• [23] Thiotepa FDA Label
• [24] Triamcinolone FDA Label
• [25] Vinblastine FDA Label
• [26] Vincristine FDA Label
• [27] Circulating miR-421 Targeting Leucocytic Angiotensin Converting Enzyme 2 Is Elevated in Patients with Chronic Kidney Disease.Nephron. 2019;141(1):61-74. doi: 10.1159/000493805. Epub 2018 Oct 16.
• [28] Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas.Blood. 2002 Jun 1;99(11):4094-9. doi: 10.1182/blood.v99.11.4094.
• [29] CAR-T cells beyond CD19, UnCAR-Ted territory.Am J Hematol. 2019 May;94(S1):S34-S41. doi: 10.1002/ajh.25398. Epub 2019 Jan 23.
• [30] EBV transformation overrides gene expression patterns of B cell differentiation stages.Mol Immunol. 2008 Jun;45(11):3133-41. doi: 10.1016/j.molimm.2008.03.002. Epub 2008 Apr 21.
• [31] Generation of a human induced pluripotent stem cell line (PHAi003) from a primary immunodeficient patient with CD70 mutation.Stem Cell Res. 2019 Dec;41:101612. doi: 10.1016/j.scr.2019.101612. Epub 2019 Oct 25.
• [32] Reciprocal Cdc25A and p27 expression in B-cell non-Hodgkin lymphomas.Diagn Mol Pathol. 2003 Sep;12(3):128-32. doi: 10.1097/00019606-200309000-00003.
• [33] Dipeptidyl peptidase IV: serum activity and expression on lymphocytes in different hematological malignancies.Leuk Lymphoma. 2013 Dec;54(12):2701-6. doi: 10.3109/10428194.2013.782611. Epub 2013 Apr 19.
• [34] Identification of novel genes in Hirschsprung disease pathway using whole genome expression study.J Pediatr Surg. 2012 Feb;47(2):303-7. doi: 10.1016/j.jpedsurg.2011.11.017.
• [35] GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities.Appl Immunohistochem Mol Morphol. 2019 Mar;27(3):180-184. doi: 10.1097/PAI.0000000000000581.
• [36] Medical conditions in Ashkenazi schizophrenic pedigrees.Schizophr Bull. 1994;20(3):507-17. doi: 10.1093/schbul/20.3.507.
• [37] Cooperative epigenetic modulation by cancer amplicon genes.Cancer Cell. 2010 Dec 14;18(6):590-605. doi: 10.1016/j.ccr.2010.11.013.
• [38] A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus.Nat Commun. 2014 Jun 12;5:3856. doi: 10.1038/ncomms4856.
• [39] Performance of a novel high sensitivity cardiac troponin I assay in asymptomatic hemodialysis patients - evidence for sex-specific differences.Clin Chem Lab Med. 2019 Jul 26;57(8):1261-1270. doi: 10.1515/cclm-2018-1176.
• [40] Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma.Leuk Lymphoma. 2012 Oct;53(10):1934-44. doi: 10.3109/10428194.2012.682307. Epub 2012 May 22.
• [41] HIV-1 remission following CCR532/32 haematopoietic stem-cell transplantation.Nature. 2019 Apr;568(7751):244-248. doi: 10.1038/s41586-019-1027-4. Epub 2019 Mar 5.
• [42] CD95 ligand is expressed in Reed-Sternberg cells of Hodgkin's disease.Pathol Int. 1999 Feb;49(2):103-9. doi: 10.1046/j.1440-1827.1999.00830.x.
• [43] Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities.Blood. 2009 Nov 12;114(20):4503-6. doi: 10.1182/blood-2009-06-225839. Epub 2009 Sep 4.
• [44] Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients.Int Urol Nephrol. 2019 Mar;51(3):519-526. doi: 10.1007/s11255-018-2050-3. Epub 2018 Dec 24.
• [45] Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells.Oncoimmunology. 2018 Jan 19;7(5):e1421889. doi: 10.1080/2162402X.2017.1421889. eCollection 2018.
• [46] Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study.HIV Med. 2018 Jun 4. doi: 10.1111/hiv.12624. Online ahead of print.
• [47] Potential Correlation Between Circulating Fetuin-A and Pentraxin-3 With Biochemical Parameters of Calcification in Hemodialysis Patients.Arch Iran Med. 2017 Dec 1;20(12):752-755.
• [48] Expression of activation-induced cytidine deaminase in malignant lymphomas infiltrating the bone marrow.Appl Immunohistochem Mol Morphol. 2008 Dec;16(6):521-9. doi: 10.1097/PAI.0b013e3181758ce5.
• [49] Vascular adhesion protein-1 in hemodialysis and hemodiafiltration patients: effect of single hemodialysis session on its level in regard to type of anticoagulant.Int Urol Nephrol. 2017 May;49(5):875-879. doi: 10.1007/s11255-016-1497-3. Epub 2017 Jan 2.
• [50] Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment.Eur J Clin Invest. 2002 Jun;32(6):421-8. doi: 10.1046/j.1365-2362.2002.00996.x.
• [51] Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.Sci Rep. 2017 Jan 23;7:41071. doi: 10.1038/srep41071.
• [52] Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.Blood. 2002 Feb 15;99(4):1474-7. doi: 10.1182/blood.v99.4.1474.
• [53] Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.Eur J Haematol. 2017 Oct;99(4):378-380. doi: 10.1111/ejh.12911. Epub 2017 Jul 5.
• [54] Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?.Pract Radiat Oncol. 2019 May;9(3):179-187. doi: 10.1016/j.prro.2019.01.006. Epub 2019 Jan 29.
• [55] Characterization of Hodgkin's lymphoma-like undifferentiated carcinoma of the nasopharyngeal type as a particular UCNT subtype mimicking Hodgkin's lymphoma.Int J Oncol. 2003 Jul;23(1):97-103.
• [56] Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.J Clin Pharmacol. 2020 Jan;60(1):58-66. doi: 10.1002/jcph.1564. Epub 2019 Dec 16.
• [57] Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis.Pathology. 2020 Jan;52(1):154-165. doi: 10.1016/j.pathol.2019.09.005. Epub 2019 Nov 5.
• [58] Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.Blood. 2018 Oct 4;132(14):1495-1506. doi: 10.1182/blood-2018-04-842708. Epub 2018 Aug 8.
• [59] A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas.Mol Syst Biol. 2008;4:169. doi: 10.1038/msb.2008.2. Epub 2008 Feb 12.
• [60] Immunoglobulin and T cell receptor beta chain gene rearrangements and Epstein-Barr viral DNA in tissues of Hodgkin's disease in Taiwan.Int J Hematol. 1993 Jun;57(3):251-7.
• [61] CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse.Genes Immun. 2016 Sep;17(6):363-6. doi: 10.1038/gene.2016.30. Epub 2016 Jul 28.
• [62] CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma. Haematologica. 2018 Apr;103(4):655-665.
• [63] A modified version of galectin-9 induces cell cycle arrest and apoptosis of Burkitt and Hodgkin lymphoma cells.Br J Haematol. 2008 Aug;142(4):583-94. doi: 10.1111/j.1365-2141.2008.07229.x. Epub 2008 May 22.
• [64] CDKN2 (MTS1/p16INK4A) gene alterations in hematological malignancies.Leuk Lymphoma. 1997 Feb;24(5-6):449-61. doi: 10.3109/10428199709055583.
• [65] Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas.Blood. 2004 Mar 15;103(6):2351-7. doi: 10.1182/blood-2003-07-2356. Epub 2003 Nov 26.
• [66] Smaller low-density lipoprotein size as a possible risk factor for the prevalence of coronary artery diseases in haemodialysis patients: associations of cholesteryl ester transfer protein and the hepatic lipase gene polymorphism with low-density lipoprotein size.Nephrology (Carlton). 2011 Aug;16(6):558-66. doi: 10.1111/j.1440-1797.2011.01454.x.
• [67] Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. Leuk Res. 2008 Feb;32(2):275-85. doi: 10.1016/j.leukres.2007.05.024. Epub 2007 Jul 19.
• [68] Expression of A New Endogenous Retrovirus-Associated Transcript in Hodgkin Lymphoma Cells.Int J Mol Sci. 2019 Oct 25;20(21):5320. doi: 10.3390/ijms20215320.
• [69] CXCR5 and ICOS expression identifies a CD8 T-cell subset with T(FH) features in Hodgkin lymphomas.Blood Adv. 2018 Aug 14;2(15):1889-1900. doi: 10.1182/bloodadvances.2018017244.
• [70] Activated DDR1 increases RS cell survival.Blood. 2013 Dec 19;122(26):4152-4. doi: 10.1182/blood-2013-11-534123.
• [71] DRD3 variation associates with early-onset heroin dependence, but not specific personality traits.Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jun 3;51:1-8. doi: 10.1016/j.pnpbp.2013.12.018. Epub 2014 Jan 5.
• [72] The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues.Haematologica. 2009 Sep;94(9):1307-11. doi: 10.3324/haematol.2009.008045.
• [73] Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells.Blood. 2005 Sep 15;106(6):2138-46. doi: 10.1182/blood-2005-02-0471. Epub 2005 Jun 2.
• [74] Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas.Oncogene. 2007 Jun 21;26(29):4243-52. doi: 10.1038/sj.onc.1210211. Epub 2007 Jan 29.
• [75] Inflammation induces osteoclast differentiation from peripheral mononuclear cells in chronic kidney disease patients: crosstalk between the immune and bone systems.Nephrol Dial Transplant. 2018 Jan 1;33(1):65-75. doi: 10.1093/ndt/gfx222.
• [76] Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone.N Engl J Med. 1992 Apr 23;326(17):1115-22. doi: 10.1056/NEJM199204233261704.
• [77] Differential Impacts of Intravenous Iron Administration and Iron-Containing Phosphate Binders on Serum Intact Fibroblast Growth Factor 23 Levels.Blood Purif. 2019;47 Suppl 2:63-69. doi: 10.1159/000496640. Epub 2019 Apr 3.
• [78] High expression of FMNL1 protein in T non-Hodgkin's lymphomas.Leuk Res. 2006 Jun;30(6):735-8. doi: 10.1016/j.leukres.2005.10.003. Epub 2006 Feb 21.
• [79] Deregulated FOX genes in Hodgkin lymphoma.Genes Chromosomes Cancer. 2014 Nov;53(11):917-33. doi: 10.1002/gcc.22204. Epub 2014 Jul 17.
• [80] Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients.Kidney Blood Press Res. 2010;33(1):30-6. doi: 10.1159/000285845. Epub 2010 Feb 23.
• [81] Monomorphic lymphomas arising in patients with Hodgkin's disease. Correlation of morphologic, immunophenotypic, and molecular genetic findings in 12 cases.Am J Pathol. 1990 Jan;136(1):81-94.
• [82] Prevalence of circulating CD4+CD28null T cells is associated with early atherosclerotic damage in patients with end-stage renal disease undergoing hemodialysis.Hum Immunol. 2013 Jan;74(1):6-13. doi: 10.1016/j.humimm.2012.08.001. Epub 2012 Aug 16.
• [83] Association of Hepcidin With Anemia Parameters in Incident Dialysis Patients: Differences Between Dialysis Modalities.Ther Apher Dial. 2020 Feb;24(1):4-16. doi: 10.1111/1744-9987.12837. Epub 2019 Jun 10.
• [84] Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas.Ann Oncol. 2009 Aug;20(8):1408-13. doi: 10.1093/annonc/mdp006. Epub 2009 May 22.
• [85] Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.J Clin Oncol. 2017 Jun 20;35(18):1999-2007. doi: 10.1200/JCO.2016.70.9410. Epub 2017 Apr 18.
• [86] The associations of HLA-A, -B, DRB1 alleles and haplotypes in Turkish lymphoma patients.Gene. 2016 Jul 25;586(2):263-7. doi: 10.1016/j.gene.2016.04.017. Epub 2016 Apr 7.
• [87] HLA-G peptide preferences change in transformed cells: impact on the binding motif.Immunogenetics. 2018 Aug;70(8):485-494. doi: 10.1007/s00251-018-1058-2. Epub 2018 Mar 30.
• [88] Genome wide association study identifies novel potential candidate genes for bovine milk cholesterol content.Sci Rep. 2018 Sep 5;8(1):13239. doi: 10.1038/s41598-018-31427-0.
• [89] RNA Related Pathology in Huntington's Disease.Adv Exp Med Biol. 2018;1049:85-101. doi: 10.1007/978-3-319-71779-1_4.
• [90] Aberrant expression of ID2 protein and its correlation with EBV-LMP1 and P16(INK4A) in classical Hodgkin lymphoma in China.BMC Cancer. 2008 Dec 19;8:379. doi: 10.1186/1471-2407-8-379.
• [91] Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.Int J Artif Organs. 2008 Apr;31(4):295-302. doi: 10.1177/039139880803100404.
• [92] Interferon-3 as a Predictor of Survival in Hemodialysis Patients.Curr Mol Med. 2018;18(4):207-215. doi: 10.2174/1566524018666180926162324.
• [93] Gene expression profile of cytokines and chemokines in microdissected primary Hodgkin and Reed-Sternberg (HRS) cells: high expression of interleukin-11 receptor alpha.Ann Oncol. 2006 Jan;17(1):110-6. doi: 10.1093/annonc/mdj064. Epub 2005 Nov 15.
• [94] Polymorphisms of T helper cell cytokine-associated genes and survival of hemodialysis patients - a prospective study.BMC Nephrol. 2017 May 19;18(1):165. doi: 10.1186/s12882-017-0582-x.
• [95] 3' untranslated region A>C (rs3212227) polymorphism of Interleukin 12B gene as a potential risk factor for Hodgkin's lymphoma in Brazilian children and adolescents.Tumour Biol. 2019 Jul;41(7):1010428319860400. doi: 10.1177/1010428319860400.
• [96] Epstein-Barr virus latent membrane protein-1 up-regulates cytokines and correlates with older age and poorer prognosis in Hodgkin lymphoma.Histopathology. 2017 Feb;70(3):442-455. doi: 10.1111/his.13085. Epub 2016 Nov 8.
• [97] Suppression of an IL-13 autocrine growth loop in a human Hodgkin/Reed-Sternberg tumor cell line by a novel IL-13 antagonist.Cell Immunol. 2001 Jul 10;211(1):37-42. doi: 10.1006/cimm.2001.1828.
• [98] Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients.Oncotarget. 2017 Jul 28;8(49):85263-85275. doi: 10.18632/oncotarget.19665. eCollection 2017 Oct 17.
• [99] IL4R and IL13 polymorphic variants and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to HBV vaccination or infection.Vaccine. 2013 Apr 3;31(14):1766-70. doi: 10.1016/j.vaccine.2013.02.023. Epub 2013 Feb 24.
• [100] Mechanisms of aberrant GATA3 expression in classical Hodgkin lymphoma and its consequences for the cytokine profile of Hodgkin and Reed/Sternberg cells.Blood. 2010 Nov 18;116(20):4202-11. doi: 10.1182/blood-2010-01-265827. Epub 2010 Jul 26.
• [101] Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.BMC Cancer. 2019 Nov 10;19(1):1080. doi: 10.1186/s12885-019-6303-z.
• [102] Association of killer cell immunoglobulin-like receptor genes with Hodgkin's lymphoma in a familial study.PLoS One. 2007 May 2;2(5):e406. doi: 10.1371/journal.pone.0000406.
• [103] Immunoglobulin gene rearrangement analysis in composite hodgkin disease and large B-cell lymphoma: evidence for receptor revision of immunoglobulin heavy chain variable region genes in Hodgkin-Reed-Sternberg cells?.Diagn Mol Pathol. 2002 Mar;11(1):2-8. doi: 10.1097/00019606-200203000-00002.
• [104] Expression of C-type lectin receptor mRNA in otitis media with effusion and chronic otitis media with and without cholesteatoma.Auris Nasus Larynx. 2019 Oct;46(5):672-680. doi: 10.1016/j.anl.2018.12.011. Epub 2019 Jan 1.
• [105] Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma.Blood. 2012 Jun 7;119(23):5478-91. doi: 10.1182/blood-2012-01-403154. Epub 2012 Apr 19.
• [106] Vitamin E suppresses 5-lipoxygenase-mediated oxidative stress in peripheral blood mononuclear cells of hemodialysis patients regardless of administration route. Am J Kidney Dis. 2001 May;37(5):964-9. doi: 10.1016/s0272-6386(05)80012-5.
• [107] Hodgkin's lymphoma cell lines express a fusion protein encoded by intergenically spliced mRNA for the multilectin receptor DEC-205 (CD205) and a novel C-type lectin receptor DCL-1.J Biol Chem. 2003 Sep 5;278(36):34035-41. doi: 10.1074/jbc.M303112200. Epub 2003 Jun 24.
• [108] The role of chemokines in Hodgkin's disease.Leuk Lymphoma. 2000 Jul;38(3-4):363-71. doi: 10.3109/10428190009087027.
• [109] The MAZ protein is an autoantigen of Hodgkin's disease and paraneoplastic cerebellar dysfunction.Ann Neurol. 2003 Jan;53(1):123-7. doi: 10.1002/ana.10434.
• [110] Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.Arch Dermatol. 2007 Apr;143(4):495-9. doi: 10.1001/archderm.143.4.495.
• [111] Significance of serum Myostatin in hemodialysis patients.BMC Nephrol. 2019 Dec 11;20(1):462. doi: 10.1186/s12882-019-1647-9.
• [112] A novel MspI PCR-RFLP in the human cytosine 5-methyltransferase gene: lack of relevance for malignant lymphoproliferative disease and breast cancer.Hum Hered. 1998 Jul-Aug;48(4):226-9. doi: 10.1159/000022805.
• [113] Risk Factors for Primary Arteriovenous Fistula Dysfunction in Hemodialysis Patients: A Retrospective Survival Analysis in Multiple Medical Centers.Blood Purif. 2019;48(3):276-282. doi: 10.1159/000500045. Epub 2019 May 8.
• [114] Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.APMIS. 2011 Apr;119(4-5):296-303. doi: 10.1111/j.1600-0463.2011.02733.x. Epub 2011 Mar 25.
• [115] Analysis of NFKB2mediated regulation of mechanisms underlying the development of Hodgkin's lymphoma.Mol Med Rep. 2018 Jun;17(6):8129-8136. doi: 10.3892/mmr.2018.8911. Epub 2018 Apr 20.
• [116] Mutations of NFKBIA in biopsy specimens from Hodgkin lymphoma.Cancer Genet Cytogenet. 2010 Mar;197(2):152-7. doi: 10.1016/j.cancergencyto.2009.11.005.
• [117] nm23-H1 protein expression and gene mutation in 150 patients with non-Hodgkin's lymphomas.J Korean Med Sci. 2006 Aug;21(4):645-51. doi: 10.3346/jkms.2006.21.4.645.
• [118] Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas.Cancers (Basel). 2017 Aug 3;9(8):100. doi: 10.3390/cancers9080100.
• [119] Calcium-sensing receptor gene (CASR) polymorphisms and CASR transcript level concerning dyslipidemia in hemodialysis patients: a cross-sectional study.BMC Nephrol. 2019 Nov 27;20(1):436. doi: 10.1186/s12882-019-1619-0.
• [120] PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.Blood. 2008 Mar 15;111(6):3220-4. doi: 10.1182/blood-2007-05-085159. Epub 2008 Jan 18.
• [121] Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.Mol Cancer. 2015 Dec 8;14:205. doi: 10.1186/s12943-015-0477-z.
• [122] Analysis of mismatch repair defects in the familial occurrence of lymphoma and colorectal cancer.Leuk Lymphoma. 2002 Aug;43(8):1619-26. doi: 10.1080/1042819021000002956.
• [123] Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells.PLoS One. 2013;8(2):e55897. doi: 10.1371/journal.pone.0055897. Epub 2013 Feb 11.
• [124] A roadmap of constitutive NF-B activity in Hodgkin lymphoma: Dominant roles of p50 and p52 revealed by genome-wide analyses.Genome Med. 2016 Mar 17;8(1):28. doi: 10.1186/s13073-016-0280-5.
• [125] Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.Cytotherapy. 2019 Feb;21(2):212-223. doi: 10.1016/j.jcyt.2018.08.001. Epub 2018 Nov 2.
• [126] Impact of Weekly Teriparatide on the Bone and Mineral Metabolism in Hemodialysis Patients With Relatively Low Serum Parathyroid Hormone: A Pilot Study.Ther Apher Dial. 2020 Apr;24(2):146-153. doi: 10.1111/1744-9987.12867. Epub 2019 Jul 21.
• [127] Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.Nat Genet. 2014 Apr;46(4):329-35. doi: 10.1038/ng.2900. Epub 2014 Feb 16.
• [128] Infrainguinal bypass surgery outcomes are worse in hemodialysis patients compared with patients with renal transplants.J Vasc Surg. 2019 Mar;69(3):850-856. doi: 10.1016/j.jvs.2018.05.252. Epub 2018 Dec 21.
• [129] A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3).Nat Genet. 2010 Dec;42(12):1126-1130. doi: 10.1038/ng.696. Epub 2010 Oct 31.
• [130] Expression of the novel all-trans retinoic acid-related resistance gene HA117 in pediatric solid tumors.J Pediatr Hematol Oncol. 2014 Jan;36(1):45-50. doi: 10.1097/MPH.0b013e31828e5d73.
• [131] Associations between Soluble Receptor for Advanced Glycation End Products (sRAGE) and S100A12 (EN-RAGE) with Mortality in Long-term Hemodialysis Patients.J Korean Med Sci. 2017 Jan;32(1):54-59. doi: 10.3346/jkms.2017.32.1.54.
• [132] A novel variant of SLC26A4 and first report of the c.716T>A variant in Iranian pedigrees with non-syndromic sensorineural hearing loss.Am J Otolaryngol. 2018 Nov-Dec;39(6):719-725. doi: 10.1016/j.amjoto.2018.07.022. Epub 2018 Jul 27.
• [133] Prognostic Utility of the IPS 3 Score for Predicting Outcomes in Advanced Hodgkin Lymphoma.Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):116-122. doi: 10.1016/j.clml.2018.11.009. Epub 2018 Nov 13.
• [134] Differential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease.Leuk Lymphoma. 2002 Jul;43(7):1435-40. doi: 10.1080/1042819022386725.
• [135] Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis.Am J Kidney Dis. 2004 Jun;43(6):1030-9. doi: 10.1053/j.ajkd.2004.02.016.
• [136] Influence of SLCO1B3 gene polymorphism on the pharmacokinetics of digoxin in terminal renal failure.Drug Metab Pharmacokinet. 2008;23(6):406-11. doi: 10.2133/dmpk.23.406.
• [137] The restricted expression pattern of the Hodgkin's lymphoma-associated cytokine receptor CD30 is regulated by a minimal promoter.J Pathol. 2000 Oct;192(2):182-93. doi: 10.1002/1096-9896(2000)9999:9999<::AID-PATH691>3.0.CO;2-X.
• [138] Diagnostic utility of STAT6(YE361) expression in classical Hodgkin lymphoma and related entities.Mod Pathol. 2020 May;33(5):834-845. doi: 10.1038/s41379-019-0428-0. Epub 2019 Dec 10.
• [139] T-bet, a T cell-associated transcription factor, is expressed in Hodgkin's lymphoma.Hum Pathol. 2005 Jan;36(1):10-5. doi: 10.1016/j.humpath.2004.10.006.
• [140] Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.BMC Cancer. 2018 Dec 4;18(1):1209. doi: 10.1186/s12885-018-5111-1.
• [141] Mutation analysis of tumor necrosis factor alpha-induced protein 3 gene in Hodgkin lymphoma.Pathol Res Pract. 2017 Mar;213(3):256-260. doi: 10.1016/j.prp.2016.11.001. Epub 2016 Nov 26.
• [142] Validating Body Fat Assessment by Bioelectric Impedance Spectroscopy in Taiwanese Hemodialysis Patients.J Ren Nutr. 2017 Jan;27(1):37-44. doi: 10.1053/j.jrn.2016.08.003. Epub 2016 Sep 22.
• [143] A new death receptor 3 isoform: expression in human lymphoid cell lines and non-Hodgkin's lymphomas.Biochem Biophys Res Commun. 1998 Jan 14;242(2):376-9. doi: 10.1006/bbrc.1997.7948.
• [144] Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.Blood. 2007 Jan 15;109(2):729-39. doi: 10.1182/blood-2006-04-015958. Epub 2006 Sep 7.
• [145] Dietary Tryptophan Induces Opposite Health-Related Responses in the Senegalese Sole (Solea senegalensis) Reared at Low or High Stocking Densities With Implications in Disease Resistance.Front Physiol. 2019 May 1;10:508. doi: 10.3389/fphys.2019.00508. eCollection 2019.
• [146] Concurrent Hodgkin's disease (mixed cellularity type) and T-cell chronic lymphocytic leukemia/prolymphocytic leukemia.Int J Hematol. 2001 Feb;73(2):230-5. doi: 10.1007/BF02981943.
• [147] Three-color flow cytometry in the diagnosis of malignant lymphoma based on the comparative cell morphology of lymphoma cells and reactive lymphocytes.Leukemia. 1997 Nov;11(11):1891-903. doi: 10.1038/sj.leu.2400802.
• [148] Potential cardiovascular risk protection of bilirubin in end-stage renal disease patients under hemodialysis.Biomed Res Int. 2014;2014:175286. doi: 10.1155/2014/175286. Epub 2014 Sep 10.
• [149] Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW.Clin Cancer Res. 2017 Nov 15;23(22):7119-7129. doi: 10.1158/1078-0432.CCR-17-1144. Epub 2017 Aug 29.
• [150] T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.Blood. 2009 Jun 18;113(25):6392-402. doi: 10.1182/blood-2009-03-209650. Epub 2009 Apr 17.
• [151] Mutational status of EZH2 and CD79B hot spots in mature B-cell non-Hodgkin's lymphomas: novel CD79B variations have been revealed.Eur Rev Med Pharmacol Sci. 2016 Mar;20(5):830-6.
• [152] Jun activation domain-binding protein 1 negatively regulate p27 kip1 in non-Hodgkin's lymphomas.Cancer Biol Ther. 2008 Mar;7(3):460-7. doi: 10.4161/cbt.7.3.5456. Epub 2007 Dec 21.
• [153] In vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1, while CD40 ligand and IL-4 induce LMP-1 but not EBNA-2.Int J Cancer. 2005 Mar 1;113(6):937-45. doi: 10.1002/ijc.20654.
• [154] Pustular eruption associated with granulocyte colony-stimulating factor treatment.G Ital Dermatol Venereol. 2018 Apr;153(2):276-277. doi: 10.23736/S0392-0488.16.05084-7. Epub 2016 Nov 15.
• [155] Elevated soluble CD23 level indicates increased risk of B cell non-Hodgkin's lymphomas: evidence from a meta-analysis.Ann Hematol. 2018 Aug;97(8):1317-1325. doi: 10.1007/s00277-018-3349-y. Epub 2018 May 11.
• [156] The poor insane Ophelia: reconsidering Ophelia syndrome.Arq Neuropsiquiatr. 2019 Nov;77(11):828-831. doi: 10.1590/0004-282X20190105.
• [157] Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1.Blood Cancer J. 2019 Jan 15;9(2):6. doi: 10.1038/s41408-018-0168-2.
• [158] Combined hyperlipidemia: familial but not (usually) monogenic.Curr Opin Lipidol. 2016 Apr;27(2):131-40. doi: 10.1097/MOL.0000000000000270.
• [159] Investigating the Contribution of NPSR1, IL-6 and BDNF Polymorphisms to Depressive and Anxiety Symptoms in Hemodialysis Patients.Prog Neuropsychopharmacol Biol Psychiatry. 2019 Aug 30;94:109657. doi: 10.1016/j.pnpbp.2019.109657. Epub 2019 May 25.
• [160] A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression.Cancer Immunol Immunother. 2019 Mar;68(3):421-432. doi: 10.1007/s00262-018-2282-1. Epub 2018 Dec 18.
• [161] Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.Blood. 2017 Sep 21;130(12):1418-1429. doi: 10.1182/blood-2017-01-760702. Epub 2017 Jul 11.
• [162] Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.Ann Hematol. 2018 Jul;97(7):1229-1240. doi: 10.1007/s00277-018-3283-z. Epub 2018 Feb 26.
• [163] Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine.Oncotarget. 2015 Oct 6;6(30):28693-715. doi: 10.18632/oncotarget.4981.
• [164] Alterations of loci encoding PU.1, BOB1, and OCT2 transcription regulators do not correlate with their suppressed expression in Hodgkin lymphoma.Cancer Genet Cytogenet. 2005 Apr 15;158(2):167-71. doi: 10.1016/j.cancergencyto.2004.09.005.
• [165] Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells.Front Oncol. 2019 Sep 24;9:945. doi: 10.3389/fonc.2019.00945. eCollection 2019.
• [166] Hodgkin's disease variant of Richter's syndrome clonally related to chronic lymphocytic leukemia arises in ZAP-70 negative mutated CLL.Med Hypotheses. 2006;66(3):577-9. doi: 10.1016/j.mehy.2005.09.007. Epub 2005 Oct 11.
• [167] Transfection of caspase-3 in the caspase-3-deficient Hodgkin's disease cell line, KMH2, results in enhanced sensitivity to CD95-, TRAIL-, and ARA-C-induced apoptosis.Exp Hematol. 2001 May;29(5):572-81. doi: 10.1016/s0301-472x(01)00627-0.
• [168] Frequency distribution of BLMH, XPO5 and HFE gene polymorphisms in the South Indian population and their association with Hodgkin Lymphoma.Int J Biol Markers. 2018 Mar 1:1724600818766502. doi: 10.1177/1724600818766502. Online ahead of print.
• [169] Role of polymorphisms of GSTM1, GSTT1 and GSTP1 Ile105Val in Hodgkin and non-Hodgkin lymphoma risk: a Human Genome Epidemiology (HuGE) review.Leuk Lymphoma. 2013 Jan;54(1):14-20. doi: 10.3109/10428194.2012.706284. Epub 2012 Aug 13.
• [170] Interleukin-12 expression in human lymphomas and nonneoplastic lymphoid disorders.Blood. 1995 Apr 15;85(8):2182-8.
• [171] Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression.Leuk Lymphoma. 2018 May;59(5):1143-1152. doi: 10.1080/10428194.2017.1369073. Epub 2017 Sep 7.
• [172] High incidence of monoclonal EBV episomes in Hodgkin's disease and anaplastic large-cell KI-1-positive lymphomas in HIV-1-positive patients.Int J Cancer. 1993 Apr 22;54(1):53-9. doi: 10.1002/ijc.2910540110.
• [173] Ectopic expression of transcription factor BATF3 induces B-cell lymphomas in a murine B-cell transplantation model.Oncotarget. 2018 Mar 23;9(22):15942-15951. doi: 10.18632/oncotarget.24639. eCollection 2018 Mar 23.
• [174] Forecast post-dialysis blood pressure in hemodialysis patients with intradialytic hypertension.Clin Exp Hypertens. 2019;41(6):571-576. doi: 10.1080/10641963.2018.1523916. Epub 2018 Oct 16.
• [175] Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial.Hematol Oncol. 2020 Feb;38(1):67-73. doi: 10.1002/hon.2693. Epub 2020 Jan 13.
• [176] Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study.J Clin Med. 2019 Apr 16;8(4):523. doi: 10.3390/jcm8040523.
• [177] Aberrant expression of NKL homeobox gene HLX in Hodgkin lymphoma.Oncotarget. 2018 Feb 16;9(18):14338-14353. doi: 10.18632/oncotarget.24512. eCollection 2018 Mar 6.
• [178] Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.J Oncol Pharm Pract. 2020 Mar;26(2):478-480. doi: 10.1177/1078155219852146. Epub 2019 May 29.
• [179] Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14920-5. doi: 10.1073/pnas.0904231106. Epub 2009 Aug 12.
• [180] Increased expression of germinal center-associated nuclear protein RNA-primase is associated with lymphomagenesis.Cancer Res. 2005 Jul 1;65(13):5925-34. doi: 10.1158/0008-5472.CAN-04-3259.
• [181] Development of lymphoma in Autoimmune Lymphoproliferative Syndrome (ALPS) and its relationship to Fas gene mutations.Leuk Lymphoma. 2004 Mar;45(3):423-31. doi: 10.1080/10428190310001593166.
• [182] Loss of RASGRP1 in humans impairs T-cell expansion leading to Epstein-Barr virus susceptibility.EMBO Mol Med. 2018 Feb;10(2):188-199. doi: 10.15252/emmm.201708292.
• [183] Contribution of Common Variants in GABRG2, RELN and NRG3 and Interaction Networks to the Risk of Hirschsprung Disease.Cell Physiol Biochem. 2016;40(3-4):509-526. doi: 10.1159/000452565. Epub 2016 Nov 25.
• [184] The cellular homologue of the transforming gene of SKV avian retrovirus maps to human chromosome region 1q22----q24.Cytogenet Cell Genet. 1986;43(3-4):181-6. doi: 10.1159/000132318.
• [185] Biomarkers of Cardiovascular Risk in Haemodialysis Patients.Curr Pharm Des. 2018 Feb 12;23(39):6086-6095. doi: 10.2174/1381612823666170816114816.
• [186] Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility.Nat Commun. 2017 Dec 1;8(1):1892. doi: 10.1038/s41467-017-00320-1.
• [187] Expression of human tumor-associated antigen RCAS1 in Reed-Sternberg cells in association with Epstein-Barr virus infection: a potential mechanism of immune evasion.Int J Cancer. 2001 Jul 1;93(1):91-6. doi: 10.1002/ijc.1300.
• [188] Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk.Genes Immun. 2006 Dec;7(8):615-24. doi: 10.1038/sj.gene.6364337. Epub 2006 Sep 14.
• [189] Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis Patients.Biol Trace Elem Res. 2020 Jan;193(1):14-22. doi: 10.1007/s12011-019-01685-8. Epub 2019 Mar 7.
• [190] Audiological findings, genotype and clinical severity score in Cornelia de Lange syndrome.Int J Pediatr Otorhinolaryngol. 2014 Jul;78(7):1045-8. doi: 10.1016/j.ijporl.2014.03.038. Epub 2014 Apr 8.
• [191] OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation.PLoS One. 2008 Aug 20;3(8):e2990. doi: 10.1371/journal.pone.0002990.
• [192] Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22.Br J Haematol. 2008 Mar;140(5):527-36. doi: 10.1111/j.1365-2141.2007.06964.x.
• [193] CD26, together with cell surface adenosine deaminase, is selectively expressed on ALK-positive, but not on ALK-negative, anaplastic large cell lymphoma and Hodgkin's lymphoma.Leuk Lymphoma. 2006 Oct;47(10):2181-8. doi: 10.1080/10428190600773396.
• [194] Characterization of add(1)(p36) in non-Hodgkin lymphomas by fluorescence in situ hybridization.Genes Chromosomes Cancer. 1995 May;13(1):34-9. doi: 10.1002/gcc.2870130106.
• [195] Polymorphisms and expression of genes encoding Argonautes 1 and 2 in autoimmune thyroid diseases.Autoimmunity. 2018 Feb;51(1):35-42. doi: 10.1080/08916934.2017.1416468. Epub 2017 Dec 19.
• [196] Characterization of Alstrom Syndrome 1 (ALMS1) Transcript Variants in Hodgkin Lymphoma Cells.PLoS One. 2017 Jan 30;12(1):e0170694. doi: 10.1371/journal.pone.0170694. eCollection 2017.
• [197] Assignment of the human MAD and MXI1 genes to chromosomes 2p12-p13 and 10q24-q25.Genomics. 1994 Sep 1;23(1):282-5. doi: 10.1006/geno.1994.1496.
• [198] Role of a single haemopoietic growth factor in multiple proliferative disorders of haemopoietic and related cells.Lancet. 1984 Jul 21;2(8395):133-7. doi: 10.1016/s0140-6736(84)91049-3.
• [199] The role of p73 in hematological malignancies.Leukemia. 2006 May;20(5):757-66. doi: 10.1038/sj.leu.2404166.
• [200] Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma.Br J Haematol. 2007 Oct;139(2):217-23. doi: 10.1111/j.1365-2141.2007.06782.x.
• [201] Analysis of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) gene and promoter in Hodgkin's disease isolates: selection against EBV variants with mutations in the LMP-1 promoter ATF-1/CREB-1 binding site.Mol Pathol. 2000 Oct;53(5):280-8. doi: 10.1136/mp.53.5.280.
• [202] In-vivo induction of monocyte chemotactic and activating factor in patients with chronic renal failure.Nephrol Dial Transplant. 1995 Dec;10(12):2244-9. doi: 10.1093/ndt/10.12.2244.
• [203] BCL10 in malignant lymphomas--an evaluation using fluorescence in situ hybridization.J Pathol. 2002 Jan;196(1):59-66. doi: 10.1002/path.1015.
• [204] BCL2 and BCL3 are recurrent translocation partners of the IGH locus.Cancer Genet Cytogenet. 2008 Oct 15;186(2):110-4. doi: 10.1016/j.cancergencyto.2008.06.007.
• [205] Chronic Myeloid Leukemia as Secondary Malignancy Following the Treatment of Hodgkin Lymphoma: A Case Series.Anticancer Res. 2019 Aug;39(8):4333-4335. doi: 10.21873/anticanres.13600.
• [206] Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO).Leukemia. 2002 May;16(5):894-901. doi: 10.1038/sj.leu.2402484.
• [207] Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma.Nat Med. 2010 May;16(5):571-9, 1p following 579. doi: 10.1038/nm.2129. Epub 2010 May 2.
• [208] Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas.Int J Cancer. 2002 Jun 10;99(5):665-72. doi: 10.1002/ijc.10399.
• [209] Expression of signal-transducing zeta chain in peripheral blood T cells and natural killer cells in patients with Hodgkin's disease in different phases of the disease.Leuk Lymphoma. 1999 Nov;35(5-6):545-54. doi: 10.1080/10428199909169619.
• [210] SEPTIN2 and STATHMIN Regulate CD99-Mediated Cellular Differentiation in Hodgkin's Lymphoma.PLoS One. 2015 May 22;10(5):e0127568. doi: 10.1371/journal.pone.0127568. eCollection 2015.
• [211] Human non-Hodgkin's lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent kinase inhibitor p21.Blood. 1997 Apr 1;89(7):2523-8.
• [212] Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.Histopathology. 2018 Jun;72(7):1156-1163. doi: 10.1111/his.13475. Epub 2018 Mar 9.
• [213] Factors influencing survival time of hemodialysis patients; time to event analysis using parametric models: a cohort study.BMC Nephrol. 2019 Jun 11;20(1):215. doi: 10.1186/s12882-019-1382-2.
• [214] Hemodialysis patient characteristics associated with better experience as measured by the In-center Hemodialysis Consumer Assessment of Healthcare Providers and Systems (ICH CAHPS) survey.BMC Nephrol. 2018 Nov 28;19(1):340. doi: 10.1186/s12882-018-1147-3.
• [215] Cux1 transcription factor is induced in inflammatory bowel disease and protects against experimental colitis.Inflamm Bowel Dis. 2010 Oct;16(10):1739-50. doi: 10.1002/ibd.21274.
• [216] Reduced pro-inflammatory responses to Staphylococcus aureus bloodstream infection and low prevalence of enterotoxin genes in isolates from patients on haemodialysis.Eur J Clin Microbiol Infect Dis. 2017 Jan;36(1):33-42. doi: 10.1007/s10096-016-2767-9. Epub 2016 Sep 9.
• [217] Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B).Mol Cancer. 2010 Jan 26;9:14. doi: 10.1186/1476-4598-9-14.
• [218] WebHERV: A Web Server for the Computational Investigation of Gene Expression Associated With Endogenous Retrovirus-Like Sequences.Front Microbiol. 2018 Nov 5;9:2384. doi: 10.3389/fmicb.2018.02384. eCollection 2018.
• [219] Expression of Foxo3a in non-Hodgkin's lymphomas is correlated with cell cycle inhibitor p27.Eur J Haematol. 2008 Aug;81(2):83-93. doi: 10.1111/j.1600-0609.2008.01077.x. Epub 2008 Mar 19.
• [220] MicroRNA-24-3p regulates Hodgkin's lymphoma cell proliferation, migration and invasion by targeting DEDD.Oncol Lett. 2019 Jan;17(1):365-371. doi: 10.3892/ol.2018.9599. Epub 2018 Oct 19.
• [221] DIXDC1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) via enhancing p-Akt in Non-Hodgkin's lymphomas.Leuk Res. 2016 Nov;50:104-111. doi: 10.1016/j.leukres.2016.09.011. Epub 2016 Sep 8.
• [222] Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas.J Transl Med. 2012 Oct 11;10:209. doi: 10.1186/1479-5876-10-209.
• [223] Estrogen receptor ligation inhibits Hodgkin lymphoma growth by inducing autophagy.Oncotarget. 2017 Jan 31;8(5):8522-8535. doi: 10.18632/oncotarget.14338.
• [224] DICER and DROSHA gene expression and polymorphisms in autoimmune thyroid diseases.Autoimmunity. 2016 Dec;49(8):514-522. doi: 10.1080/08916934.2016.1230846. Epub 2016 Nov 3.
• [225] Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NFkappaB transcription factors.J Pathol. 2004 Dec;204(5):528-37. doi: 10.1002/path.1661.
• [226] Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma.Leukemia. 2013 Mar;27(3):671-9. doi: 10.1038/leu.2012.280. Epub 2012 Oct 1.
• [227] Expression of the translation initiation factors eIF-4E and eIF-2* is frequently increased in neoplastic cells of Hodgkin lymphoma.Hum Pathol. 2008 Jun;39(6):910-6. doi: 10.1016/j.humpath.2007.10.021. Epub 2008 Jan 30.
• [228] Antibiotic Prophylaxis for Melioidosis in Patients Receiving Hemodialysis in the Tropics? One Size Does Not Fit All.Am J Trop Med Hyg. 2018 Sep;99(3):597-600. doi: 10.4269/ajtmh.18-0421. Epub 2018 Jul 12.
• [229] Germinal center-specific protein human germinal center associated lymphoma directly interacts with both myosin and actin and increases the binding of myosin to actin.FEBS J. 2011 Jun;278(11):1922-31. doi: 10.1111/j.1742-4658.2011.08109.x. Epub 2011 Apr 20.
• [230] Rare disease knowledge enrichment through a data-driven approach.BMC Med Inform Decis Mak. 2019 Feb 14;19(1):32. doi: 10.1186/s12911-019-0752-9.
• [231] Hodgkin's lymphoma cells exhibit high expression levels of the PICOT protein.J Immunotoxicol. 2010 Mar;7(1):8-14. doi: 10.3109/15476910903427654.
• [232] Simultaneous intrinsic signal imaging of auditory and visual cortex reveals profound effects of acute hearing loss on visual processing.Neuroimage. 2017 Oct 1;159:459-472. doi: 10.1016/j.neuroimage.2017.07.037. Epub 2017 Jul 20.
• [233] Human Regulatory Protein Ki-1/57 Is a Target of SUMOylation and Affects PML Nuclear Body Formation.J Proteome Res. 2017 Sep 1;16(9):3147-3157. doi: 10.1021/acs.jproteome.7b00001. Epub 2017 Jul 31.
• [234] Hodgkin lymphoma and Epstein-Barr virus (EBV): no evidence to support hit-and-run mechanism in cases classified as non-EBV-associated.Int J Cancer. 2003 May 1;104(5):624-30. doi: 10.1002/ijc.10979.
• [235] Expression of p55 (Tac) interleukin-2 receptor (IL-2R), but not p75 IL-2R, in cultured H-RS cells and H-RS cells in tissues.Am J Pathol. 1990 Apr;136(4):735-44.
• [236] Aberrant Huntingtin interacting protein 1 in lymphoid malignancies.Cancer Res. 2007 Sep 15;67(18):8923-31. doi: 10.1158/0008-5472.CAN-07-2153.
• [237] Relationship of serum haemojuvelin and hepcidin levels with iron level and erythropoietin requirement in prevalent hepatitis C virus positive haemodialysis patients.Nephrology (Carlton). 2018 Apr;23(4):323-330. doi: 10.1111/nep.13010.
• [238] HLA alleles, especially amino-acid signatures of HLA-DPB1, might contribute to the molecular pathogenesis of early-onset autoimmune thyroid disease.PLoS One. 2019 May 15;14(5):e0216941. doi: 10.1371/journal.pone.0216941. eCollection 2019.
• [239] Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1.Blood. 2007 Apr 1;109(7):3015-23. doi: 10.1182/blood-2006-08-044347.
• [240] Restin in Hodgkin's disease and anaplastic large cell lymphoma.Leuk Lymphoma. 1993 Dec;12(1-2):21-6. doi: 10.3109/10428199309059567.
• [241] Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile.Neoplasia. 2009 Feb;11(2):167-76. doi: 10.1593/neo.08980.
• [242] Increased Act1/IL-17R expression in Hirschsprung's disease.Pediatr Surg Int. 2016 Dec;32(12):1201-1207. doi: 10.1007/s00383-016-3980-4. Epub 2016 Sep 22.
• [243] CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies.Cancers (Basel). 2019 Sep 12;11(9):1358. doi: 10.3390/cancers11091358.
• [244] The role of mitofilin in left ventricular hypertrophy in hemodialysis patients.Ren Fail. 2018 Nov;40(1):252-258. doi: 10.1080/0886022X.2018.1456455.
• [245] ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complex.Mol Cancer. 2014 Jul 29;13:181. doi: 10.1186/1476-4598-13-181.
• [246] Expression of the follicular lymphoma variant translocation 1 gene in diffuse large B-cell lymphoma correlates with subtype and clinical outcome.Am J Clin Pathol. 2008 Dec;130(6):957-62. doi: 10.1309/AJCP12HIRWSRQLAN.
• [247] Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.Am Heart J. 2005 Dec;150(6):1154-62. doi: 10.1016/j.ahj.2005.02.006.
• [248] MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis.Am J Clin Pathol. 2006 May;125(5):776-82. doi: 10.1309/98KL-HRDA-M5CM-DHE2.
• [249] Blocking the association of HDAC4 with MAP1S accelerates autophagy clearance of mutant Huntingtin.Aging (Albany NY). 2015 Oct;7(10):839-53. doi: 10.18632/aging.100818.
• [250] Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.Lancet Haematol. 2018 Oct;5(10):e462-e473. doi: 10.1016/S2352-3026(18)30140-6.
• [251] Hodgkin Lymphoma in a Patient With IFAP Syndrome: A Case Report and Review of Literature.J Pediatr Hematol Oncol. 2018 Apr;40(3):227-230. doi: 10.1097/MPH.0000000000000894.
• [252] Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity.MAbs. 2019 Aug/Sep;11(6):1149-1161. doi: 10.1080/19420862.2019.1618674. Epub 2019 Jun 4.
• [253] MEF2 transcription factors: developmental regulators and emerging cancer genes.Oncotarget. 2016 Jan 19;7(3):2297-312. doi: 10.18632/oncotarget.6223.
• [254] Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas.Am J Surg Pathol. 2018 Mar;42(3):342-350. doi: 10.1097/PAS.0000000000001015.
• [255] Apoptosis and cell cycle-related genes and proteins in classical Hodgkin lymphoma: application of tissue microarray technique.Appl Immunohistochem Mol Morphol. 2003 Sep;11(3):206-13. doi: 10.1097/00129039-200309000-00002.
• [256] HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3.Leukemia. 2005 May;19(5):841-6. doi: 10.1038/sj.leu.2403716.
• [257] MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas.Br J Haematol. 2007 Aug;138(4):479-86. doi: 10.1111/j.1365-2141.2007.06680.x. Epub 2007 Jun 29.
• [258] An intronic deletion in megakaryoblastic leukemia 1 is associated with hyperproliferation of B cells in triplets with Hodgkin lymphoma.Haematologica. 2020 May;105(5):1339-1350. doi: 10.3324/haematol.2019.216317. Epub 2019 Oct 3.
• [259] KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells. Mol Cancer Ther. 2014 Jun;13(6):1611-24. doi: 10.1158/1535-7163.MCT-13-0649. Epub 2014 Mar 31.
• [260] Aberrant expression of napsin A in a subset of malignant lymphomas.Histol Histopathol. 2016 Feb;31(2):213-21. doi: 10.14670/HH-11-669. Epub 2015 Sep 24.
• [261] TT virus infection and genotype distribution in blood donors and a group of patients from Turkey.Infection. 2002 Oct;30(5):299-302. doi: 10.1007/s15010-002-2185-z.
• [262] Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas.Cancer Res. 2005 Jun 1;65(11):4554-61. doi: 10.1158/0008-5472.CAN-04-4108.
• [263] NKL homeobox gene NKX2-2 is aberrantly expressed in Hodgkin lymphoma.Oncotarget. 2018 Dec 25;9(101):37480-37496. doi: 10.18632/oncotarget.26459. eCollection 2018 Dec 25.
• [264] Exome sequencing reveals germline NPAT mutation as a candidate risk factor for Hodgkin lymphoma.Blood. 2011 Jul 21;118(3):493-8. doi: 10.1182/blood-2011-03-341560. Epub 2011 May 11.
• [265] Interaction between the Haptoglobin 2 Phenotype and Diabetes Mellitus on Systolic Pulmonary Arterial Pressure and Nitric Oxide Bioavailability in Hemodialysis Patients.J Diabetes Res. 2015;2015:613860. doi: 10.1155/2015/613860. Epub 2015 Jun 11.
• [266] Aberrantly Expressed OTX Homeobox Genes Deregulate B-Cell Differentiation in Hodgkin Lymphoma.PLoS One. 2015 Sep 25;10(9):e0138416. doi: 10.1371/journal.pone.0138416. eCollection 2015.
• [267] Comparison of QuantiFERON-TB Gold In-Tube (QFT-GIT) and tuberculin skin test (TST) for diagnosis of latent tuberculosis in haemodialysis (HD) patients: a meta-analysis of estimates.Epidemiol Infect. 2017 Jul;145(9):1824-1833. doi: 10.1017/S0950268817000334. Epub 2017 Mar 2.
• [268] Pregnancy-Associated Plasma Protein A2 in Hemodialysis Patients: Significance for Prognosis.Kidney Blood Press Res. 2017;42(3):509-518. doi: 10.1159/000479847. Epub 2017 Aug 30.
• [269] High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas.Blood. 2012 Feb 9;119(6):1479-89. doi: 10.1182/blood-2011-07-370841. Epub 2011 Dec 13.
• [270] Inevitable isolation and the change of stress markers in hemodialysis patients during the 2015 MERS-CoV outbreak in Korea.Sci Rep. 2019 Apr 5;9(1):5676. doi: 10.1038/s41598-019-41964-x.
• [271] DNA polymerase mu gene expression in B-cell non-Hodgkin's lymphomas: an analysis utilizing in situ hybridization.Am J Pathol. 2002 Oct;161(4):1349-55. doi: 10.1016/s0002-9440(10)64411-2.
• [272] Germline mutations in Protection of Telomeres 1 in two families with Hodgkin lymphoma.Br J Haematol. 2018 May;181(3):372-377. doi: 10.1111/bjh.15203.
• [273] Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma.Blood. 2018 Nov 8;132(19):2040-2052. doi: 10.1182/blood-2018-06-855296. Epub 2018 Sep 7.
• [274] POU4F3 mutation screening in Japanese hearing loss patients: Massively parallel DNA sequencing-based analysis identified novel variants associated with autosomal dominant hearing loss.PLoS One. 2017 May 17;12(5):e0177636. doi: 10.1371/journal.pone.0177636. eCollection 2017.
• [275] Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells.J Pathol. 2003 Nov;201(3):413-20. doi: 10.1002/path.1454.
• [276] Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell lines.Mol Cancer. 2008 Jan 7;7:2. doi: 10.1186/1476-4598-7-2.
• [277] Expression of human recombination activating genes (RAG-1 and RAG-2) in Hodgkin's disease.Blood. 1992 Dec 1;80(11):2867-72.
• [278] Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma. PLoS One. 2013 Nov 6;8(11):e79863. doi: 10.1371/journal.pone.0079863. eCollection 2013.
• [279] Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively.J Cancer Res Clin Oncol. 2019 Jun;145(6):1437-1448. doi: 10.1007/s00432-019-02909-z. Epub 2019 Apr 2.
• [280] Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma.Blood. 2006 Aug 1;108(3):1013-20. doi: 10.1182/blood-2005-10-3949. Epub 2006 Apr 13.
• [281] Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy.Cardiovasc Res. 2017 May 1;113(6):598-608. doi: 10.1093/cvr/cvw245.
• [282] Expression of housekeeping genes in Hodgkin's disease lymph nodes.Leukemia. 1991 Dec;5(12):1110-2.
• [283] Characteristics, survival and incidence rates and trends of primary cardiac malignancies in the United States.Cardiovasc Pathol. 2018 Mar-Apr;33:27-31. doi: 10.1016/j.carpath.2017.12.001. Epub 2017 Dec 28.
• [284] Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays.Mod Pathol. 2006 May;19(5):684-94. doi: 10.1038/modpathol.3800577.
• [285] Flow cytometric measurements of proliferation-associated nuclear antigen p105 and DNA content in non-Hodgkin's lymphomas.Arch Pathol Lab Med. 1989 Aug;113(8):907-11.
• [286] Alterations of Spermatozoa Proteomic Profile in Men with Hodgkin's Disease Prior to Cancer Therapy.World J Mens Health. 2020 Oct;38(4):521-534. doi: 10.5534/wjmh.190012. Epub 2019 Jun 14.
• [287] Expression of SH2D1A in five classical Hodgkin's disease-derived cell lines.Int J Cancer. 2003 May 1;104(5):658-61. doi: 10.1002/ijc.10986.
• [288] Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin's lymphoma in mice.Arch Biochem Biophys. 2018 Jun 15;648:12-19. doi: 10.1016/j.abb.2018.04.012. Epub 2018 Apr 18.
• [289] A novel frameshift mutation of SMPX causes a rare form of X-linked nonsyndromic hearing loss in a Chinese family.PLoS One. 2017 May 25;12(5):e0178384. doi: 10.1371/journal.pone.0178384. eCollection 2017.
• [290] Autocrine LTA signaling drives NF-B and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma.Blood. 2019 Mar 28;133(13):1489-1494. doi: 10.1182/blood-2018-08-871293. Epub 2019 Jan 29.
• [291] Paraneoplastic limbic encephalitis with SOX1 and PCA2 antibodies and relapsing neurological symptoms in an adolescent with Hodgkin lymphoma.Eur J Paediatr Neurol. 2017 Jul;21(4):661-665. doi: 10.1016/j.ejpn.2017.03.005. Epub 2017 Mar 27.
• [292] Aberrant expression of homeobox gene SIX1 in Hodgkin lymphoma.Oncotarget. 2015 Nov 24;6(37):40112-26. doi: 10.18632/oncotarget.5556.
• [293] Relation of serum spondin-2 levels with cardiac morphology and inflammatory parameters in hemodialysis patients.Int Urol Nephrol. 2018 Nov;50(11):2091-2097. doi: 10.1007/s11255-018-1996-5. Epub 2018 Oct 1.
• [294] Expression of SSX genes in the neoplastic cells of Hodgkin's lymphoma.Hum Pathol. 2002 May;33(5):496-502. doi: 10.1053/hupa.2002.124909.
• [295] Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.Clin Cancer Res. 2020 Mar 1;26(5):1034-1044. doi: 10.1158/1078-0432.CCR-19-1768. Epub 2019 Dec 6.
• [296] Defects in middle ear cavitation cause conductive hearing loss in the Tcof1 mutant mouse.Hum Mol Genet. 2010 Apr 15;19(8):1551-60. doi: 10.1093/hmg/ddq028. Epub 2010 Jan 27.
• [297] CD30 ligand deficiency accelerates glioma progression by promoting the formation of tumor immune microenvironment.Int Immunopharmacol. 2019 Jun;71:350-360. doi: 10.1016/j.intimp.2019.03.055. Epub 2019 Apr 2.
• [298] Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.Clin Rheumatol. 2017 Feb;36(2):469-475. doi: 10.1007/s10067-016-3453-0. Epub 2016 Oct 20.
• [299] Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate.PLoS One. 2017 Jan 20;12(1):e0170186. doi: 10.1371/journal.pone.0170186. eCollection 2017.
• [300] Variation at 3p24.1 and 6q23.3 influences the risk of Hodgkin's lymphoma.Nat Commun. 2013;4:2549. doi: 10.1038/ncomms3549.
• [301] New fusion transcripts identified in normal karyotype acute myeloid leukemia.PLoS One. 2012;7(12):e51203. doi: 10.1371/journal.pone.0051203. Epub 2012 Dec 12.
• [302] Hodgkin and Reed-Sternberg cell-associated autoantigen CLIP-170/restin is a marker for dendritic cells and is involved in the trafficking of macropinosomes to the cytoskeleton, supporting a function-based concept of Hodgkin and Reed-Sternberg cells.Blood. 2002 Dec 1;100(12):4139-45. doi: 10.1182/blood.V100.12.4139.
• [303] Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts.Leuk Lymphoma. 2014 Jan;55(1):149-59. doi: 10.3109/10428194.2013.800196. Epub 2013 Jun 12.
• [304] Differential expression of the human MIXL1 gene product in non-Hodgkin and Hodgkin lymphomas.Hum Pathol. 2007 Mar;38(3):500-7. doi: 10.1016/j.humpath.2006.09.020.
• [305] Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.Blood. 2016 Dec 8;128(23):2666-2670. doi: 10.1182/blood-2016-03-704528. Epub 2016 Sep 26.
• [306] EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV lymphomagenesis.Leukemia. 2016 Mar;30(3):594-604. doi: 10.1038/leu.2015.285. Epub 2015 Nov 4.
• [307] Retinoblastoma gene product and P21 (WAF1, CIP1) protein expression in non Hodgkin's lymphomas: a multivariate survival analysis.Leuk Lymphoma. 2001 Feb;40(5-6):647-58. doi: 10.3109/10428190109097662.
• [308] TNF receptor-associated factor 1 is a positive regulator of the NF-kappaB alternative pathway.Mol Immunol. 2009 Oct;46(16):3278-82. doi: 10.1016/j.molimm.2009.07.029. Epub 2009 Aug 20.
• [309] TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells.Mol Immunol. 2009 Aug;46(13):2441-8. doi: 10.1016/j.molimm.2009.05.178. Epub 2009 Jun 21.